17 January 2023: Original Paper
Non-Cryopreserved Peripheral Blood Stem Cell Graft for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma and Lymphoma Patients
Panarat Noiperm ABCDEF , Jakrawadee Julamanee ABCDEFG* , Pongtep Viboonjuntra ADE , Arnuparp Lekhakula ABCDEDOI: 10.12659/AOT.938595
Ann Transplant 2023; 28:e938595
Table 1 Patient characteristics.
| Myeloma (n=40) | Lymphoma (n=18) | |
|---|---|---|
| Median age, years (range) | 57 (45–73) | 34 (17–60) |
| Gender (male to female ratio) | 17: 23 (1: 1.35) | 15: 3 (5: 1) |
| ISS risk (=38) | ||
| I | 10 (26.3) | |
| II | 11 (28.9) | |
| III | 17 (44.7) | |
| Lymphoma stage (=17) | ||
| II | 4 (22.2) | |
| III | 2 (11.1) | |
| IV | 11 (61.1) | |
| Median number of chemotherapy regimens received before ASCT (range) | 1 (1–3) | 2 (1–5) |
| ECOG score | ||
| PS 0 | 19 (47.5) | 2 (11.1) |
| PS 1 | 21 (52.5) | 15 (83.3) |
| PS 2 | 1 (5.6) | |
| HCT-CI score | ||
| 0 | 20 (50) | 8 (44.4) |
| 1–2 | 17 (42.5) | 10 (55.6) |
| 3 | 3 (7.5) | |
| Pretransplant disease status | ||
| CR | 28 (71.8) | 13 (72.2) |
| VGPR | 1 (2.6) | |
| PR | 10 (25.6) | 5 (27.8) |
| Median time from diagnosis to ASCT, months (range) | 15 (5–100) | 20 (5–97) |
| Stem cell mobilization regimen | ||
| Cyclophosphamide/G-CSF | 37 (92.5) | 14 (77.8) |
| Cyclophosphamide/Etoposide/G-CSF | 3 (7.5) | 3 (16.7) |
| ICE/G-CSF | 1 (5.6) | |
| Conditioning regimen | ||
| Melphalan 140 mg/m | 12 (30) | |
| Melphalan 200 mg/m | 28 (70) | 2 (22.2) |
| BEAM | 8 (44.4) | |
| Others | 6 (33.4) | |
| Data are presented as (%) unless otherwise indicated. ISS – international staging system; ASCT – autologous stem cell transplantation; ECOG – Eastern Cooperative Oncology Group; PS – performance status; HCT-CI – hematopoietic cell transplant-comorbidity index; CR – complete response; VGPR – very good partial response; PR – partial response; G-CSF – granulocyte-colony stimulating agents; ICE – ifosfamide-carboplatin-etoposide; BEAM – BCNU-etoposide-cytarabine-melphalan. | ||